3.05Open3.05Pre Close0 Volume2.48K Open Interest17.50Strike Price0.00Turnover256.21%IV-7.27%PremiumDec 20, 2024Expiry Date4.66Intrinsic Value100Multiplier5DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.8164Delta0.0376Gamma4.03Leverage Ratio-0.1710Theta0.0020Rho3.29Eff Leverage0.0073Vega
Grail Stock Discussion
Larger Image: tradingview.com...
$Grail (GRAL.US)$
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
No comment yet